Safety
Well tolerated and
safe for any
body location 1-3
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use1,2
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use1,2
Pivotal Safety
SAFE FOR ANY LOCATION
Low rates of stinging or burning (0.4%) in ARRECTOR3*
Not associated with folliculitis, atrophy, striae, or HPA-axis suppression1
Low rate of discontinuation due to adverse events (2.1%)4
*Low rates of hot, tingling/stinging sensation reported in patient-rated tolerability assessments 10-15 minutes after first application in ARRECTOR: 0.4% for ZORYVE foam (n=280) vs 1.4% for vehicle (n=148).
| Adverse reactions reported in ≥1% of patients treated with ZORYVE foam for 8 weeks 1 | ZORYVE (N=479) | Vehicle (N=255) |
|---|---|---|
| Headache | 3.1% | 1.2% |
| Diarrhea | 2.5% | 1.6% |
| Nausea | 1.7% | 0.0% |
| Nasopharyngitis | 1.3% | 0.8% |
Insomnia was reported in fewer than 1% of patients treated with ZORYVE.
Based on pooled safety data from ARRECTOR and Trial 204 studies.
Request a
Representative
Discover the
Elegant Formulations